Stay updated with breaking news from ஜாக்கி டோர்ஸ்கி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
electroCore Announces Peter Cuneo as Board Chairman streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to . electroCoreFebruary 9, 2021 GMT ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled: “Non-invasive vagus nerve stimulation to reduce ileus after major colorectal surgery: Early development study” in the journal Colorectal Disease. The paper reports on the results of a parallel group, randomized controlled trial conducted at St. James’s University Hospital in Leeds, England. The study was funded by the Bowel Research UK supported by the National Institute for Health Research (NIHR) Surgical MedTech Co-operative. ....
Published: Feb 02, 2021 ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) electroCore Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke. TR-VENUS is a double blind, randomized, sham-controlled, multi-center clinical trial, conducted at nine major medical centers across Turkey, supported by the Turkish Neurological Society and partially funded through an unrestricted research grant from electroCore. Stroke is the second highest cause of death and the third leading cause of disability globally . Ischemic stroke, caused by arterial occlusion, is the most common type of stroke. The effectiveness of current management strategies (e.g. rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy) is dependent on time to treatment. Treating stroke quickly and safely is imperative ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. electroCore Provides Business Update and Select Financial Guidance electroCoreJanuary 11, 2021 GMT Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M Net cash used for the fourth quarter 2020 of $3.7 million, compares favorably to previously announced guidance of $4M December 31, 2020 cash and cash equivalents of $22.6M BASKING RIDGE, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the fourth quarter. ....